ID: ALA1631123

Max Phase: Preclinical

Molecular Formula: C18H20N2OS

Molecular Weight: 312.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1/C(=C/C(=O)Nc2cccs2)c2ccccc2CC1(C)C

Standard InChI:  InChI=1S/C18H20N2OS/c1-18(2)12-13-7-4-5-8-14(13)15(20(18)3)11-16(21)19-17-9-6-10-22-17/h4-11H,12H2,1-3H3,(H,19,21)/b15-11+

Standard InChI Key:  QQUUCEXIWQGDKH-RVDMUPIBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 312.44

Molecular Weight (Monoisotopic): 312.1296

AlogP: 3.99

#Rotatable Bonds: 2

Polar Surface Area: 32.34

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.18

CX Basic pKa: 6.19

CX LogP: 3.68

CX LogD: 3.65

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.85

Np Likeness Score: -0.89

References

1. Hosokawa-Muto J, Kamatari YO, Nakamura HK, Kuwata K..  (2009)  Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.,  53  (2): [PMID:19015328] [10.1128/aac.01112-08]

2. Pagadala NS, Bjorndahl TC, Joyce M, Wishart DS, Syed K, Landi A..  (2017)  The compound (3-{5-[(2,5-dimethoxyphenyl)amino]-1,3,4-thiadiazolidin-2-yl}-5,8-methoxy-2H-chromen-2-one) inhibits the prion protein conversion from PrPC to PrPSc with lower IC50 in ScN2a cells.,  25  (20): [PMID:28951092] [10.1016/j.bmc.2017.09.024]

Source

Source(1):

• Scientific Literature